// App-Quantinova.ai

: Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Mohd Minhajuddin

Principal Investigators

  • Amanda C. Winters

  • Marc Schwartz

  • Daniel A. Pollyea

  • Craig T Jordan

Medical Centers

  • Anschutz Medical Campus, Division of Hematology, University of Colorado School of Medicine, Aurora, CO

  • University of Colorado Anschutz Medical Campus, Aurora, CO

  • University of Colorado, Aurora, CO

  • Division of Hematology, University of Colorado, Anschutz Medical Campus, RC; th floor; Room# D, CO

  • University of Colorado, Denver, CO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of differentiation 45

Drug/Treatment

  • Venetoclax

  • dasatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Efficacy

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved